Belsomra (suvorexant), Dayvigo (lemborexant), and Quviviq (daridorexant) belong to a newer drug class called dual orexin receptor antagonists, or DORAs. They work differently from Ambien and benzodiazepines. Instead of boosting the brain’s calming chemical GABA, they block orexin, the signal that keeps you awake. Trials show all three beat placebo for falling asleep and staying asleep. They also carry real side effects, and meta-analyses disagree on how often rare ones like sleep paralysis occur. Sleep guidelines still put CBT-I first for chronic insomnia. A doctor should decide whether any of these drugs fits you. This is educational information, not medical advice.
Short answer (40-60 words): Belsomra, Dayvigo, and Quviviq block orexin, the brain’s wake signal. Trials show they help people fall asleep and stay asleep better than placebo. Side effects include next-day drowsiness, and some analyses link them to sleep paralysis and vivid dreams. CBT-I remains the first-line treatment for chronic insomnia.
How Do DORAs Work?
Orexin is a brain chemical that promotes wakefulness. DORAs block the two orexin receptors, called OX1R and OX2R. That lowers the drive to stay awake. Older sleep drugs, including Ambien and benzodiazepines, calm the brain through GABA instead.
Because they work through a different system, DORAs are not linked to physiological dependence the way benzodiazepines are, according to a 2025 network meta-analysis. In the US they are still controlled substances, so doctors prescribe them with care. The FDA approved suvorexant in 2014, lemborexant in 2019, and daridorexant in 2022.
How Well Do They Work?
Two large network meta-analyses pooled randomized trials of all three drugs.
A 2025 analysis in Translational Psychiatry covered eight trials and 5,198 adults, with an average age of 56. It found moderate to high certainty evidence that suvorexant at 20 and 40 mg and daridorexant at 10 and 50 mg were the most effective at shortening the time to fall asleep. The authors suggested lemborexant 5 mg as a reasonable first option, followed by lemborexant 10 mg or suvorexant, though the right choice depends on your health and your prescriber.
A 2023 analysis in Frontiers in Pharmacology pooled nine trials and 7,257 people. All three drugs beat placebo on time to fall asleep, total sleep time, time awake after falling asleep, and the Insomnia Severity Index. Higher doses generally worked better than lower ones. The same analysis found suvorexant 10 mg had poor efficacy, despite being a labeled dose. It named suvorexant 20 mg, lemborexant 5 and 10 mg, and daridorexant 50 mg as suitable options.
At a Glance: The Three Drugs
| Drug | Brand | FDA Approved | Notes From Meta-Analyses |
|---|---|---|---|
| Suvorexant | Belsomra | 2014 | Effective at 20 and 40 mg; 10 mg showed weak efficacy |
| Lemborexant | Dayvigo | 2019 | Effective at 5 and 10 mg; some analyses rank it strongest on several outcomes |
| Daridorexant | Quviviq | 2022 | Effective at 10 and 50 mg; favorable safety profile in one analysis |
What Are the Side Effects?
Most trial participants tolerate DORAs, and serious adverse events did not rise above placebo in the major analyses. Even so, side effects happen. Common ones include next-day drowsiness, headache, and abnormal dreams. In an observational review of lemborexant, 94.7 percent of patients reported no adverse effects, and the most common ones were somnolence at 5.1 percent and nightmares at 4.9 percent.
The evidence disagrees on rarer effects. A recent meta-analysis reported a higher risk of narcolepsy-like symptoms, such as sleep paralysis, with FDA-approved DORAs than with placebo. Daridorexant showed the highest overall rate of treatment-emergent adverse events in that analysis, and lemborexant showed the highest rate of treatment-related ones. A separate network meta-analysis found no significant difference from placebo in sleep paralysis or abnormal dreams between any active drug and placebo. Researchers have not settled this point.
Drug labels also warn about next-morning impairment, so avoid driving or operating machinery until you know how a drug affects you. Labels also warn about worsening depression. Unlike Z-drugs, DORAs do not carry the FDA’s boxed warning for complex sleep behaviors. For that comparison, read our Ambien side effects guide.
How Do DORAs Compare With CBT-I?
CBT-I remains the first-line treatment. The American Academy of Sleep Medicine (AASM) gives CBT-I a strong recommendation for chronic insomnia. A 2025 AASM-commissioned review found CBT-I alone was the most effective first-line option. Adding medication gave only modest extra benefit for a few outcomes. See our CBT-I guide.
DORAs also lack strong evidence in some groups. Research on insomnia that comes with psychiatric conditions remains limited. If you take other medications, have depression or sleep apnea, or drive for work, your doctor needs to weigh those factors.
Who Might Ask Their Doctor About a DORA?
A DORA may come up when CBT-I has not worked, when you cannot access it, or when a doctor wants a non-benzodiazepine option for short-term relief. Questions to bring to your appointment:
- Why this drug instead of CBT-I or a different medication?
- How long should I take it, and how will we review it?
- What are the next-day risks for me, including driving?
- How does it interact with my other medications and supplements?
- What is the cost, and does my insurance cover this brand-name drug?
For a plain-language overview of all categories, see our sleeping pills guide. Want to talk through your options? Book a consultation with The Sleep Consultant. We do not prescribe, and we will help you prepare questions for your doctor.
What the Research Shows
DORAs beat placebo for insomnia. A 2023 network meta-analysis of 9 trials and 7,257 people found all three drugs improved time to fall asleep, total sleep time, and insomnia severity.
Doses matter. The same analysis found suvorexant 10 mg had poor efficacy, while suvorexant 20 mg, lemborexant 5 and 10 mg, and daridorexant 50 mg worked well.
Serious adverse events did not rise above placebo. Both major meta-analyses found no increase in serious adverse events, though minor effects like drowsiness and abnormal dreams occurred.
Evidence on rare effects conflicts. One meta-analysis found more narcolepsy-like symptoms with DORAs, while another found no significant difference in sleep paralysis or nightmares.
This article is for educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment.
If you would like to see how we might be able to help you with this deeper, schedule a free consult here.
Want a Free Starting Point?
Join the free sleep course and community: Join the Sleep Nirvana Club
When to Seek Professional Help
- You are thinking about starting, stopping, or changing a sleep medication
- You feel groggy the morning after a dose or notice sleep paralysis or vivid hallucinations
- You have depression, sleep apnea, or a history of substance use alongside insomnia
- Your insomnia has lasted three months or longer without a clear plan
- You drive for work or operate machinery
Frequently Asked Questions
What are Belsomra, Dayvigo, and Quviviq?
They are prescription insomnia drugs called dual orexin receptor antagonists. Belsomra is suvorexant, Dayvigo is lemborexant, and Quviviq is daridorexant. They block orexin, the brain signal that promotes wakefulness.
Are these drugs better than Ambien?
They work through a different system, and they are not linked to physiological dependence the way benzodiazepines are. Direct superiority over Ambien is not established in the evidence I reviewed. They do not carry the FDA’s boxed warning for complex sleep behaviors that Z-drugs carry.
What are the side effects of DORAs?
Common effects include next-day drowsiness, headache, and abnormal dreams. Some analyses link DORAs to sleep paralysis and other narcolepsy-like symptoms, while another found no significant difference from placebo. Labels also warn about worsening depression.
Should I take a DORA instead of doing CBT-I?
Guidelines put CBT-I first for chronic insomnia. A 2025 AASM-commissioned review found CBT-I alone worked best, and adding medication gave only modest extra benefit. A doctor can help you decide if a drug makes sense alongside or after CBT-I.
Is it safe to stop a DORA on my own?
Talk to your prescriber before you change or stop any prescription sleep medication. Your doctor can plan the change and help you manage how your sleep feels afterward.
When to Work With a Sleep Consultant
Newer drugs add options, but they do not replace a plan. If you want help preparing for a medication conversation, or building habits that support your sleep, we can help.
